Related Experiment Video
Updated: Aug 11, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Elizabeth A Griffiths1, Vivek Roy2, Laura Alwan3
1Roswell Park Comprehensive Cancer Center.
Abstract:
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
Related Concept Videos
Hematopoiesis
Multipotency of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

